<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32994544</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5403</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cell death and differentiation</Title><ISOAbbreviation>Cell Death Differ</ISOAbbreviation></Journal><ArticleTitle>Genetic inactivation of RIP1 kinase does not ameliorate disease in a mouse model of ALS.</ArticleTitle><Pagination><StartPage>915</StartPage><EndPage>931</EndPage><MedlinePgn>915-931</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41418-020-00625-7</ELocationID><Abstract><AbstractText>RIP1 kinase is proposed to play a critical role in driving necroptosis and inflammation in neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS). Preclinical studies indicated that while pharmacological inhibition of RIP1 kinase can ameliorate axonal pathology and delay disease onset in the mutant SOD1 transgenic (SOD1-Tg) mice, genetic blockade of necroptosis does not provide benefit in this mouse model. To clarify the role of RIP1 kinase activity in driving pathology in SOD1-Tg mice, we crossed SOD1-Tgs to RIP1 kinase-dead knock-in mice, and measured disease progression using functional and histopathological endpoints. Genetic inactivation of the RIP1 kinase activity in the SOD1-Tgs did not benefit the declining muscle strength or nerve function, motor neuron degeneration or neuroinflammation. In addition, we did not find evidence of phosphorylated RIP1 accumulation in the spinal cords of ALS patients. On the other hand, genetic inactivation of RIP1 kinase activity ameliorated the depletion of the neurotransmitter dopamine in a toxin model of dopaminergic neurodegeneration. These findings indicate that RIP1 kinase activity is dispensable for disease pathogenesis in the SOD1-Tg mice while inhibition of kinase activity may provide benefit in acute injury models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dominguez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varfolomeev</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendza</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tea</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imperio</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earr</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Oded</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Easton</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Domagoj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingol</LastName><ForeName>Baris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, Inc., South San Francisco, CA, 94080, USA. barisb@gene.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Differ</MedlineTA><NlmUniqueID>9437445</NlmUniqueID><ISSNLinking>1350-9047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490620">Ralbp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020690" MajorTopicYN="N">GTPase-Activating Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>TE and BB are former and all other authors are current employees of Genentech, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32994544</ArticleId><ArticleId IdType="pmc">PMC7937687</ArticleId><ArticleId IdType="doi">10.1038/s41418-020-00625-7</ArticleId><ArticleId IdType="pii">10.1038/s41418-020-00625-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martens S, Hofmans S, Declercq W, Augustyns K, Vandenabeele P. Inhibitors targeting RIPK1/RIPK3: old and new drugs. Trends Pharmacol Sci. 2020;41:209&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">32035657</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. 2019;116:9714&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525537</ArticleId><ArticleId IdType="pubmed">31048504</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Hitomi J, Germscheid M, Ch&#x2019;en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="pubmed">18408713</ArticleId></ArticleIdList></Reference><Reference><Citation>Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van T-M, et al. Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol. 2014;193:1539&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119562</ArticleId><ArticleId IdType="pubmed">25015821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Ito Y, Najafov A, Zhang Y, Shan B, DeWitt JP, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10:1836&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer R, Laurien L, Pasparakis M. New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8. Curr Opin Cell Biol. 2020;63:186&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32163825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao Y-S, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012;150:339&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664196</ArticleId><ArticleId IdType="pubmed">22817896</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">19524512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112&#x2013;23..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727676</ArticleId><ArticleId IdType="pubmed">19524513</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213&#x2013;27..</Citation><ArticleIdList><ArticleId IdType="pubmed">22265413</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Liu H, Johnston A, Hanna-Addams S, Reynoso E, Xiang Y, et al. MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis. Proc Natl Acad Sci USA. 2017;114:E7450&#x2013;E9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5594682</ArticleId><ArticleId IdType="pubmed">28827318</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39:443&#x2013;53..</Citation><ArticleIdList><ArticleId IdType="pubmed">24012422</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 2020;27:161&#x2013;75..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206119</ArticleId><ArticleId IdType="pubmed">31101885</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, Dugger D, Maltzman A, Greve J, Hedehus M, Martin-McNulty B, et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 2016;23:1565&#x2013;76..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072432</ArticleId><ArticleId IdType="pubmed">27177019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lule S, Wu L, McAllister LM, Edmiston WJ, III, Chung JY, Levy E, et al. Genetic inhibition of RIPK1 reduces cell death and improves functional outcome after intracerebral hemorrhage in mice. Stroke. 2017;48:2549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366458</ArticleId><ArticleId IdType="pubmed">28765287</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Sarmah D, Mounica L, Kaur H, Kesharwani R, Verma G, et al. Cell death pathways in ischemic stroke and targeted pharmacotherapy. Transl Stroke Res. 2020:1&#x2013;18. 10.1007/s12975-020-00806-z.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219729</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Pan H, Li J, Xu H, Jin H, Qian C, et al. Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: possibly through alleviating necroptosis. Biomedicine Pharmacother. 2018;107:563&#x2013;70..</Citation><ArticleIdList><ArticleId IdType="pubmed">30114640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang H, Tao Y, Zhang S, Wang J, Feng X. Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury. Neuroscience. 2014;266:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">24561219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Zhang Y, Bai G, Li H. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington&#x2019;s disease. Cell Death Dis. 2011;2:e115&#x2013;e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043604</ArticleId><ArticleId IdType="pubmed">21359116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2017;114:E8788&#x2013;E97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642727</ArticleId><ArticleId IdType="pubmed">28904096</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, et al. Necroptosis activation in Alzheimer&#x2019;s disease. Nat Neurosci. 2017;20:1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">28758999</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson&#x2019;s disease models. Cell Rep. 2018;22:2066&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5842028</ArticleId><ArticleId IdType="pubmed">29466734</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Jin T, Zhu H, Chen H, Ofengeim D, Zou C, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell. 2018;174:1477&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128749</ArticleId><ArticleId IdType="pubmed">30146158</ArticleId></ArticleIdList></Reference><Reference><Citation>Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81:1001&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951532</ArticleId><ArticleId IdType="pubmed">24508385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa M, Saitoh M, Katoh T, Seki T, Bigi SV, Shimizu Y, et al. Discovery of 7-oxo-2, 4, 5, 7-tetrahydro-6 H-pyrazolo [3, 4-c] pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure&#x2013;kinetic relationships. J Med Chem. 2018;61:2384&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">29485864</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JD, Vucic D. The balance of TNF mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues. Front Cell Dev Biol. 2020;8:365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326080</ArticleId><ArticleId IdType="pubmed">32671059</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermentzaki G, Politi KA, Lu L, Mishra V, P&#xe9;rez-Torres EJ, Sosunov AA, et al. Deletion of Ripk3 prevents Motor Neuron death in vitro but not in vivo. eneuro. 2019;6:ENEURO.0308-18.2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391588</ArticleId><ArticleId IdType="pubmed">30815534</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathologica. 2015;130:77&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng SM, Che CH, Feng SY, Liu CY, Li LY, Li YX, et al. Novel mutation in optineurin causing aggressive ALS+/&#x2212; frontotemporal dementia. Annals of Clinical and Translational. Neurology. 2019;6:2377&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917321</ArticleId><ArticleId IdType="pubmed">31838784</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2015;69:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Perera ND, Chiam MD, Cuic B, Wanniarachchillage N, Tomas D, et al. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell Death Differ. 2019;27:1728&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206015</ArticleId><ArticleId IdType="pubmed">31745214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56:481&#x2013;95..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4512186</ArticleId><ArticleId IdType="pubmed">25459880</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343:1357&#x2013;60..</Citation><ArticleIdList><ArticleId IdType="pubmed">24557836</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta-Ghosh A, Dominguez SL, Xie L, Barck KH, Jiang Z, Earr T, et al. Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1G93A mouse model of ALS. Neurobiol Dis. 2019;124:340&#x2013;52..</Citation><ArticleIdList><ArticleId IdType="pubmed">30528255</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almagro MC, Goncharov T, Izrael-Tomasevic A, Duttler S, Kist M, Varfolomeev E, et al. Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death. Cell Death Differ. 2017;24:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260504</ArticleId><ArticleId IdType="pubmed">27518435</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, Meilandt WJ, Dominguez S, Solanoy H, Lin H, Ngu H, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:eaag0394.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Veta M, Van Diest PJ, Kornegoor R, Huisman A, Viergever MA, Pluim JP. Automatic nuclei segmentation in H&amp;E stained breast cancer histopathology images. PloS One. 2013;8:e70221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726421</ArticleId><ArticleId IdType="pubmed">23922958</ArticleId></ArticleIdList></Reference><Reference><Citation>De Olmos JS, Beltramino CA, De Lorenzo SDO. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicology Teratol. 1994;16:545&#x2013;61..</Citation><ArticleIdList><ArticleId IdType="pubmed">7532272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zendedel A, Beyer C, Kipp M. Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci. 2013;51:567&#x2013;72..</Citation><ArticleIdList><ArticleId IdType="pubmed">23666824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16:571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V, et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136:471&#x2013;82..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572934</ArticleId><ArticleId IdType="pubmed">23378219</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagmag SA, Tripathi N, Shukla SD, Maiti S, Khurana S. Evaluation of models of Parkinson&#x2019;s disease. Front Neurosci. 2016;9:503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718050</ArticleId><ArticleId IdType="pubmed">26834536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion&#xed;sio PA, Oliveira SR, Gaspar MM, Gama MJ, Castro-Caldas M, Amaral JD, et al. Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinson&#x2019;s disease. Cell Death Dis. 2019;10:1&#x2013;14..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6831575</ArticleId><ArticleId IdType="pubmed">31690718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Q-S, Chen P, Wang W-X, Lin C-C, Zhou Y, Yu L-H, et al. RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease. Lab Investig. 2019;100:503&#x2013;11..</Citation><ArticleIdList><ArticleId IdType="pubmed">31506635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;47..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Huang Z, Ren J, Zhang Z, He P, Li Y, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 2013;23:994&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731568</ArticleId><ArticleId IdType="pubmed">23835476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanno H, Ozawa H, Tateda S, Yahata K, Itoi E. Upregulation of the receptor-interacting protein 3 expression and involvement in neural tissue damage after spinal cord injury in mice. BMC Neurosci. 2015;16:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599321</ArticleId><ArticleId IdType="pubmed">26450067</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JD, Kwon YC, Park S, Zhang H, Corr N, Ljumanovic N, et al. RIP1 kinase activity is critical for skin inflammation but not for viral propagation. J Leukoc Biol. 2020;107:941&#x2013;52..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7317411</ArticleId><ArticleId IdType="pubmed">31985117</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlantis K, Wullaert A, Polykratis A, Kondylis V, Dannappel M, Schwarzer R, et al. NEMO prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-&#x3ba;B-dependent and-independent functions. Immunity. 2016;44:553&#x2013;67..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803910</ArticleId><ArticleId IdType="pubmed">26982364</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, et al. Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol. 2014;192:5476&#x2013;80..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4048763</ArticleId><ArticleId IdType="pubmed">24821972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickard JA, Anderton H, Etemadi N, Nachbur U, Darding M, Peltzer N, et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife. 2014;3:e03464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270099</ArticleId><ArticleId IdType="pubmed">25443632</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice JR, Gregory-Evans CY, Shaw CA. Animal models of amyotrophic lateral sclerosis: a comparison of model validity. Neural regeneration Res. 2018;13:2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP&#x2010;43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Thomson A, Falco D, Ahmad S, Staffetti J, et al. Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep. 2017;7:884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429840</ArticleId><ArticleId IdType="pubmed">28408761</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Mustafa H, Llauget A, Boccio KJ, Sanberg PR, et al. Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS. Brain Res. 2019;1724:146428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779528</ArticleId><ArticleId IdType="pubmed">31493389</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Mao M, Liu X, Shen T, Li T, Yu H, et al. A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome. J Mol Med. 2020;98:569&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32072232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A-Q, Fang Z, Chen X-L, Yang S, Zhou Y-F, Mao L, et al. Microglia-derived TNF-&#x3b1; mediates endothelial necroptosis aggravating blood brain&#x2013;barrier disruption after ischemic stroke. Cell Death Dis. 2019;10:1&#x2013;18..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6586814</ArticleId><ArticleId IdType="pubmed">31221990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelic M, Roderick JE, O&#x2019;Donnell JA, Lehman J, Lim SE, Janardhan HP, et al. RIP kinase 1&#x2013;dependent endothelial necroptosis underlies systemic inflammatory response syndrome. J Clin Investig. 2018;128:2064&#x2013;75..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919800</ArticleId><ArticleId IdType="pubmed">29664014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>